Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Director | June 16, 2026 | June 18, 2026 |
| Poseida Therapeutics, Inc.PSTX · Entity 84243 | Director | July 09, 2020 | July 13, 2020 |
| Voyager Therapeutics, Inc.VYGR · Entity 6271 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEAYA Biosciences, Inc.
Report date June 16, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.57 · Expires 2036-06-16 | Direct | 20,000 |
Reported balance
After 2026-06-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-16 · Grant · Acquired 20,000 · Balance 20,000 F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares subject to the option shall vest in full on the earlier of (i) the first anniversary of the date of grant and (ii) immediately prior to the Annual Meeting following the date of grant, subject to the Reporting Person continuing in service on the Board through such vesting date.
Poseida Therapeutics, Inc.
Report date July 09, 2020 · Filed July 13, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2030-07-08 | Direct | 20,000 |
Reported balance
After 2020-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-09 · Grant · Acquired 20,000 · Balance 20,000 F1: The stock option will vest and become exercisable in 12 equal monthly installments from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest and become exercisable in 12 equal monthly installments from the date of grant.
Voyager Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.43 · Expires 2036-06-09 | Direct | 30,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 30,000 · Balance 30,000 F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option was issued pursuant to the 2025 Stock Incentive Plan of Voyager Therapeutics, Inc. in accordance with its director compensation policy. The vesting commencement date (the "Vesting Commencement Date") of the option is the grant date. All of the shares of common stock underlying the option vest upon the earlier of the one-year anniversary of the Vesting Commencement Date or the date of the next annual meeting of stockholders, in each case subject to the Reporting Person's continued service as a director.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avid Bioservices, Inc.
Report date February 05, 2025 · Filed February 07, 2025
Section 16 reporting ended · disclosed 2025-02-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 1
1 source rowRow 1 · 2025-02-05 · Disposition to issuer · Disposed 43,379 · Balance 0 F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub. F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration"). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.38 · Expires 2026-07-25 | Direct | 29,705 |
Reported balance
After 2025-02-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-02-05 · Disposition to issuer · Disposed 32,100 · Balance 29,705 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.87 · Expires 2027-01-09 | Direct | 10,030 |
Reported balance
After 2025-02-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-02-05 · Disposition to issuer · Disposed 19,675 · Balance 10,030 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72 · Expires 2027-12-14 | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-02-05 · Disposition to issuer · Disposed 10,030 · Balance 0 F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2025-02-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-02-05 · Disposition to issuer · Disposed 8,147 · Balance 0 F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub. F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock that were disposed of at the effective time (the "Effective Time") of the merger (the "Merger") of Space Mergerco, Inc. ("Merger Sub") with and into Avid Bioservices, Inc. (the "Issuer") pursuant to the Agreement and Plan of Merger, dated as of November 6, 2024 (the "Merger Agreement"), by and among the Issuer, Space Finco, Inc., and Merger Sub.
F2: At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive a cash payment per share of $12.50, without interest, subject to the terms and conditions of the Merger Agreement (the "Merger Consideration").
F3: Represents stock options ("Options") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.
F4: This Option was fully vested at the Effective Time. At the Effective Time, each fully vested Option was cancelled and converted solely into the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such Option immediately prior to the Effective Time, multiplied by (b) the excess, if any, of the Merger Consideration over the per share exercise price of such vested Option, without interest, subject to the terms and conditions of the Merger Agreement.
F5: Represents restricted stock units ("RSUs") that were disposed of at the Effective Time of the Merger of Merger Sub with and into the Issuer pursuant to the Merger Agreement, by and among the Issuer, Space Finco, Inc., and Merger Sub.
F6: At the Effective Time, each unvested RSU was cancelled and converted solely into the right to receive a cash payment of $12.50 per share of common stock subject to such unvested RSU, without interest, subject to the terms and conditions of the Merger Agreement.
GW PHARMACEUTICALS PLC
Report date May 05, 2021 · Filed May 07, 2021
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 1
1 source rowRow 1 · 2021-05-05 · Disposition to issuer · Disposed 10,536 · Balance 0 F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2). F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $11.17 · Expires 2028-01-03 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-05 · Disposition to issuer · Disposed 35,340 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $14.33 · Expires 2029-03-01 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-05-05 · Disposition to issuer · Disposed 16,548 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-05-05 · Disposition to issuer · Disposed 3,144 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-05 · Disposition to issuer · Disposed 34,416 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4: These stock options were granted with automatic vesting on exercisable date. |
| Share OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2021-05-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-05 · Disposition to issuer · Disposed 22,464 · Balance 0 F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration. F4: These stock options were granted with automatic vesting on exercisable date. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 5, 2021, Jazz Pharmaceuticals Public Limited Company, a public limited company incorporated in the Republic of Ireland ("Jazz"), Jazz Pharmaceuticals UK Holdings Limited, a private limited company incorporated in England and Wales and an indirect wholly owned subsidiary of Jazz ("Bidco") and the DR Nominee (as defined in the Transaction Agreement) acquired all outstanding ordinary shares, par value British Pound Sterling 0.001 per share, of GW Pharmaceuticals plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement") (continued in footnote 2).
F2: At the effective time of the Scheme of Arrangement, Scheme Shareholders (as defined in the Scheme of Arrangement) became entitled to receive for each Scheme Share (as defined in the Scheme of Arrangement) held by them an amount equal to $16.66 2/3 in cash plus 0.010030 ordinary shares, nominal value $0.0001 per share, of Jazz ("Jazz ordinary shares"). The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 15, 2021.
F3: Pursuant to the Transaction Agreement, dated as of February 3, 2021 (the "Transaction Agreement"), by and among the Company, Jazz and Bidco, these share options vested (to the extent unvested) and were canceled in connection with the closing of the transactions contemplated by the Transaction Agreement in exchange for an all-cash payment equal to the value of the share options based on the value of the transaction consideration.
F4: These stock options were granted with automatic vesting on exercisable date.
SEQUENOM INC
Report date September 07, 2016 · Filed September 07, 2016
Section 16 reporting ended · disclosed 2016-09-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 1
1 source rowRow 1 · 2016-09-07 · Other · Disposed 21,114 · Balance 0 F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.11 · Expires 2026-06-14 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2016-09-07 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2026-01-03 | Direct | 0 |
Reported balance
After 2016-09-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-09-07 · Disposition to issuer · Disposed 8,571 · Balance 0 F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger").
F2: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger.
Trillium Therapeutics Inc.
Report date November 17, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.70 · Expires 2031-07-01 | Direct | 0 |
Reported balance
After 2021-11-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-11-17 · Disposition to issuer · Disposed 67,000 · Balance 0 F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash. |
Filing footnotes · ownership attribution and instrument terms
F1: On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 13, 2019 Filed Mar 15, 2019 21:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | SaleOrdinary Shares | 888 | $14.39 | $12,778.32 |
DisclosureSEC source: 0000899243-19-008029 · doc4.xml · nonDerivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,284 F4 · shares: Represented by ADSs. F5 · price: The price reported is price per ordinary share converted from price per ADS. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:08 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006338 · doc4.xml · derivative · entry 4 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:08 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006338 · doc4.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:08 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 3,144 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006338 · doc4.xml · derivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,144 Underlying: Ordinary Shares · 3,144 shares Expires not disclosed F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F4 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.32 U.S. Dollars as of March 1, 2019. F5 · derivative.expiration_date: These stock options will vest automatically on exercisable date. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:08 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | GrantStock Options · Derivative | 16,548 | $0.00 Strike: $14.33 | $0.00 |
DisclosureSEC source: 0000899243-19-006338 · doc4.xml · derivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,548 Underlying: Ordinary Shares · 16,548 shares Expires 2029-03-01 F1 · security: Granted pursuant to the Issuer's Long-Term Incentive Plan. F2 · security: The reported options are options to purchase American Depositary Shares of the Issuer ("ADS"). Each ADS represents twelve ordinary shares of the Issuer. F3 · derivative.exercise_price: The exercise price reported is price per ordinary share converted from price per ADS ($172.01). Read SEC document |
| January 03, 2019 Filed Mar 15, 2019 21:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionStock Options · Derivative | 3,580 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-008029 · doc4.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of March 13, 2019. F1 · shares: Vesting of restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018. These ordinary shares are subsequently converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Inadvertently late filing. F6 · derivative.exercise_date: The reporting person's Form 3 filed on October 1, 2018 contained stock options to purchase 10,740 ordinary shares vesting on January 3, 2021 and expiring on March 15, 2022. These securities are restricted stock units with a nominal exercise price and vest automatically upon vesting date. The correct vesting schedule of these restricted stock units is as follows: 3,580 ordinary shares vested on January 3, 2019; 3,580 ordinary shares will vest on January 3, 2020; and 3,580 ordinary shares will vest on January 3, 2021. The remaining securities following the reported transaction are reported in Column 5 of Table I. F6 · derivative.expiration_date: The reporting person's Form 3 filed on October 1, 2018 contained stock options to purchase 10,740 ordinary shares vesting on January 3, 2021 and expiring on March 15, 2022. These securities are restricted stock units with a nominal exercise price and vest automatically upon vesting date. The correct vesting schedule of these restricted stock units is as follows: 3,580 ordinary shares vested on January 3, 2019; 3,580 ordinary shares will vest on January 3, 2020; and 3,580 ordinary shares will vest on January 3, 2021. The remaining securities following the reported transaction are reported in Column 5 of Table I. F6 · balance_after: The reporting person's Form 3 filed on October 1, 2018 contained stock options to purchase 10,740 ordinary shares vesting on January 3, 2021 and expiring on March 15, 2022. These securities are restricted stock units with a nominal exercise price and vest automatically upon vesting date. The correct vesting schedule of these restricted stock units is as follows: 3,580 ordinary shares vested on January 3, 2019; 3,580 ordinary shares will vest on January 3, 2020; and 3,580 ordinary shares will vest on January 3, 2021. The remaining securities following the reported transaction are reported in Column 5 of Table I. Read SEC document |
| January 03, 2019 Filed Mar 15, 2019 21:15 UTC | GW PHARMACEUTICALS PLC GWPH · Entity 139616 | Exercise / conversionOrdinary Shares | 3,580 | $0.00 | $4.65 |
DisclosureSEC source: 0000899243-19-008029 · doc4.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,172 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Vesting of restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018. These ordinary shares are subsequently converted into American Depositary Shares ("ADS") of the Issuer. Each ADS represents twelve ordinary shares of the Issuer. Inadvertently late filing. F2 · price: Converted from British Pounds Sterling to U.S. Dollars using currency ratio of 1.00 British Pound Sterling = 1.31 U.S. Dollars as of March 13, 2019. F3 · balance_after: Includes 7,160 and 9,432 ordinary shares underlying restricted stock units previously reported as stock options on the reporting person's Form 3 filed on October 1, 2018 and Form 4 filed on March 5, 2019, respectively. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:43 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 8,571 | Not disclosed Strike: $1.60 | Not disclosed |
DisclosureSEC source: 0001209191-16-140411 · doc4.xml · derivative · entry 3 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,571 shares Expires 2026-01-03 F2 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:43 UTC | SEQUENOM INC SQNM · Entity 182543 | Disposition to issuerNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | Not disclosed Strike: $1.11 | Not disclosed |
DisclosureSEC source: 0001209191-16-140411 · doc4.xml · derivative · entry 2 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2026-06-14 F2 · price: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: This option was cancelled in the Merger in exchange for a cash payment equal to $2.40 per share (without interest) minus the per share exercise price of the option. In connection with the Merger, vesting of the option was accelerated and the option became fully vested and exercisable effective immediately prior to the effective time of the Merger. Read SEC document |
| September 07, 2016 Filed Sep 7, 2016 16:43 UTC | SEQUENOM INC SQNM · Entity 182543 | OtherCommon Stock | 21,114 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-140411 · doc4.xml · nonDerivative · entry 1 MACKEY CATHERINE J · CIK 0001645330 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated July 26, 2016, among the Issuer, Laboratory Corporation of America Holdings, a Delaware corporation ("Parent"), and Savoy Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Parent ("Purchaser") in exchange for a cash consideration of $2.40 per share, without interest, subject to any required withholding of taxes. Pursuant to the Merger Agreement, the Purchaser merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Parent (the "Merger"). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.